NDAINTRAVENOUSSOLUTION
Approved
Dec 2022
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
11
Data completeness
5/8 — Partial
BENDAMUSTINE HYDROCHLORIDE (bendamustine hydrochloride) by Fresenius Kabi is purine-like benzimidazole ring. Approved for chronic lymphocytic leukemia, non-hodgkin's lymphoma, small lymphocytic lymphoma. First approved in 2022.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Bendamustine hydrochloride is a purine-like benzimidazole alkylating agent approved for chronic lymphocytic leukemia, non-Hodgkin's lymphoma, and small lymphocytic lymphoma. It forms interstrand DNA crosslinks through covalent bonding, inducing cell death via multiple pathways and remaining active against both quiescent and dividing cells. The exact mechanism of action remains incompletely understood.
Peak
Product is in peak commercialization phase at Fresenius Kabi with moderate competitive pressure (30%), suggesting stable team size and marketing investment for the near term.
Mechanism of Action
purine-like benzimidazole ring. Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to cell death via several pathways.…
Indications (3)
Worked on BENDAMUSTINE HYDROCHLORIDE at Fresenius Kabi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.